Share

Pharma Fridays – March 15

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Topline Results Announced for CAH Studies On March 13, Spruce Biosciences announced topline results from its CAHmelia-203 study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in pediatric classic CAH. Spruce is investigating tildacerfont,...
Share

Bariatric Surgery Linked to Cardiovascular Improvements in People with Severe Obesity

Bariatric surgery may result in significant cardiometabolic improvements, particularly among younger, female, or white people and those without comorbidities, according to new research published in the Journal of the Endocrine Society. The United States has the highest obesity rates globally. In 2017 – 2018, about 40% of U.S. adults had obesity and 9% had severe obesity. The prevalence is...
Share

Laurence Katznelson, MD, Named Vice Dean, Medical Education at Cedars-Sinai

Laurence Katznelson Laurence Katznelson, MD, a national leader in graduate medical education and a distinguished physician-scientist in endocrinology and metabolism, will join Cedars-Sinai as vice dean of Medical Education on May 1. Katznelson will oversee Cedars-Sinai’s Graduate Medical Education, Continuing Medical Education, the Women’s Guild Simulation Center for Advanced Clinical Skills, the Chuck Lorre School of Allied Health, and...
Share

Endocrine Society Celebrates Special Diabetes Program Extension

The Endocrine Society applauds Congress for approving the first funding increase for the Special Diabetes Program in two decades. The U.S. Senate voted Friday March 8 to extend the program, which supports both diabetes care and research into type 1 diabetes, until the end of 2024. This is part of the six-bill package funding several...
Share

Pharma Fridays – March 8, 2024

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sandoz Receives FDA Approval for Denosumab Biosimilars On March 5, Sandoz announced that the U.S. Food and Drug Administration (FDA) approved Wyost® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz), the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines.  Keren Haruvi,...
Share

Carol Lange, PhD, Elected 2025-2026 Endocrine Society President

lange-carolphoto453x478 Endocrine Society members elected Carol Lange, PhD, of the University of Minnesota in Minneapolis, Minn., as its 2025-2026 president. She will serve as president-elect for a year beginning in June 2024 before becoming President in June 2025. A professor of medicine and molecular pharmacology and therapeutics, Lange also holds the Tickle Family Land Grant Endowed...